Anixa Biosciences Inc ANIX

NAS: ANIX | ISIN: US03528H1095   30/04/2025
2,790 USD (+1,45%)
(+1,45%)   30/04/2025

30 april 2025 · Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th · Persbericht

14 april 2025 · Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio · Persbericht

9 april 2025 · Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology · Persbericht

1 april 2025 · Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th · Persbericht

25 maart 2025 · Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines · Persbericht

24 maart 2025 · Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine · Persbericht

17 maart 2025 · Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th · Persbericht

10 maart 2025 · Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties · Persbericht

3 maart 2025 · Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th · Persbericht

3 september 2024 · Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium · Persbericht

26 augustus 2024 · Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

29 juli 2024 · Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting · Persbericht

23 juli 2024 · Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy · Persbericht

17 juli 2024 · Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology · Persbericht

15 juli 2024 · Anixa Biosciences Announces $5 Million Share Repurchase Program · Persbericht

24 juni 2024 · Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial · Persbericht

21 mei 2024 · Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial · Persbericht

8 mei 2024 · Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines · Persbericht

6 mei 2024 · Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja · Persbericht

30 april 2024 · Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 · Persbericht

Mijn selecties